PYPD

PolyPid

PYPD

Attention (50-day avg)0%

Attention rank (50-day avg)#2,604

Bullish sentiment (50-day avg)86%

Price to earnings ratio-2.53

Market capitalization107.9M

Earnings per share-1.31

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-34.2M

Social

What share of all stock conversation is about PYPD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Sep 1

Statistics show companies with over 60% success rate in phase 3 trials have over an 85% chance of being approved, with PolyPid's PDUFA fee being waived as a positive indicator.
The company's stock price is expected to hang around its current area for 2-4 weeks, with a possible drop back to $5 or climb to $5.90.
The author believes the stock has high odds for approval, with one estimate at 80% and another at 85-90%, with a 94% estimate being optimistic.

Generated by AI

Sentiment

Of the messages about PYPD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	88.24% +1.28	93.29% +8.73
Bearish	0%	0% 0	11.76% -1.28	6.71% -8.73

Bullish· Jul 23

The company's GLP-1 preclinical package is expected to be released in the next few months, potentially leading to a huge partnership deal with a big pharma company.
The company's partnership with a dedicated $1.1 billion fund for small company acquisitions and a highly qualified sales force makes it an attractive investment opportunity.
The company's GLP-1 program is expected to be a massive deal, potentially worth over $100 million in upfront payments, and will be followed by label expansion studies that will further increase the program's value.

Bearish· Jun 9

The stock has seen a significant sell-off and shorts are in control, with a notable decline in price after a promising data announcement.
The company is based in Israel, which is perceived by some as a potential red flag for pump and dump schemes.
The stock's price targets are considered meaningless, with one example of a stock having a $20 target that has instead traded under $1.

Generated by AI

Topics

Of the messages about PYPD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	83.33%	89.31%
Technical Analysis	—	0%	16.67%	2.83%
Controversies	—	0%	0%	2.83%
Analysts	—	0%	0%	2.52%
Earnings	—	0%	0%	2.52%
Macro	—	0%	0%	0%

Analysts· Sep 12

Analysts are optimistic about PolyPid Ltd. (PYPD) after the company announced presentation of Phase 2 D-PLEX₁₀₀ clinical data.
The presentation of clinical data has driven up interest in PYPD stock, with some traders considering it a resilient investment opportunity.
The European Society for Coloproctology Scientific Conference is a significant event for PolyPid Ltd., highlighting the company's presence in the medical field.

Announcements· Jun 9

PolyPid's Phase 3 SHIELD II trial of D-PLEX100 for surgical site infection prevention demonstrated a 38% reduction in primary endpoint events and met all key secondary endpoints.
The trial results showed a significant reduction in deep and superficial SSI rates, as well as a 62% reduction in patients with a high ASEPSIS score, with no safety concerns raised by the independent Data Safety Monitoring Board.
PolyPid expects to submit a New Drug Application to the FDA in early 2026 and plans to follow with a Marketing Authorization Application in the EU, with a total addressable market estimated at $6 billion in the US and $10 billion globally.

Technical Analysis· Sep 12

$PYPD is in an overextended position, but the daily chart is signaling a gap fill to $2.55 with potential for significant price movement.
The stock needs to break $1.68 to head into higher prices, with key levels to watch including $1.94 support and $2.20 resistance.
A gap fill is expected, with the next key zone at $2.55 and potential for a breakout above $2.20.

Generated by AI

Community

Of the messages about PYPD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	93.33%	57.89%	60.73%
Newcomers	0%	6.67%	42.11%	39.27%

Regulars· Aug 12

The regulars are focused on the upcoming PDUFA (PDUFA is a FDA approval process) and expect a pre-PDUFA run-up in October-November, with a potential major increase in stock price.
The company's cash position is a concern, with some users questioning the $6.6 million cash on hand when the company received $30 million from a partner, and others hoping for more transparency on the company's financials.
The regulars are optimistic about the company's future, with some users sharing inspiring messages and others celebrating the company's progress and milestones, such as the expected submission of a Marketing Authorization Application to the European Medicines Agency in Q3 2026.

Newcomers· Jul 29

The FDA has accepted PolyPid's NDA for D-PLEX₁₀₀ with Priority Review, with a target action date of November 28, 2026, and a $15 million milestone payment.
This acceptance validates the critical medical need for PolyPid's surgical infection solution and unlocks a $15 million milestone payment, with a total of $30 million in recent upfront capital.
PolyPid's cash runway has been boosted to a robust ~$41 million, eliminating near-term financing risks and funding operations comfortably into 2027.

Generated by AI

PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences: 5th Annual ROTH Healthcare Opportunities ConferenceDates: September 29, 2026Location: Metropolitan Club, New York, NYFormat: Panel discuss

15d agoYahoo Finance

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline

Tipranks Press Release.

1mo agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA) and PolyPid (PYPD)

Detailed price information for Liquidia Corp (LQDA-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...

PolyPid secures FDA Priority Review for D-Plex 100 and a $30 million upfront partnership with Azurity, positioning the company for a potential early 2027 commercial launch.

1mo agoYahoo Finance

PolyPid Ltd. Q2 2026 Earnings Call Summary

Moby summary of PolyPid Ltd.'s Q2 2026 earnings call

1mo agoYahoo Finance

Also Discussed

Investors talking about PYPD also mention

#	Name	Attention
1	Coya Therapeutics, Inc.COYA	0%+0
2	Cingulate Inc.CING	0%new
3	Gain Therapeutics, Inc.GANX	0.04%+0.02
4	Gossamer Bio Inc.GOSS	0%+0
5	Alpha Tau Medical Ltd.DRTS	0%+0
6	SELLAS Life Sciences Group, Inc.SLS	0.56%-0.06
7	Harrow Inc.HROW	0%0
8	Greenwich LifeSciences, Inc.GLSI	0%0
9	MGAM - Mobile Global Esports Inc.	——
10	UroGen Pharma Ltd.URGN	0%new

PolyPid Ltd.

Healthcare
Biotechnology

PolyPid Ltd. is a biopharmaceutical company focused on developing long-acting, locally administered therapeutics designed to deliver treatment precisely at the site of care. Its core platform, PLEX, is used to create controlled-release drug formulations that aim to improve therapeutic performance and address unmet medical needs across surgical care and other specialty areas. The company’s lead product candidate, D-PLEX100, is being developed for the prevention of surgical site infections, while its pipeline also includes oncology-focused programs such as OncoPLEX. PolyPid Ltd. works across clinical development, formulation design, and drug delivery technology, positioning itself in the broader market for targeted medicines and advanced pharmaceutical delivery systems. The company is headquartered in Petach Tikva, Israel.

Website

Location

18 Hasivim Street

Petah Tikva, 4959376

Israel

Social

What share of all stock conversation is about PYPD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Sep 1

Statistics show companies with over 60% success rate in phase 3 trials have over an 85% chance of being approved, with PolyPid's PDUFA fee being waived as a positive indicator.
The company's stock price is expected to hang around its current area for 2-4 weeks, with a possible drop back to $5 or climb to $5.90.
The author believes the stock has high odds for approval, with one estimate at 80% and another at 85-90%, with a 94% estimate being optimistic.

Generated by AI

Sentiment

Of the messages about PYPD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	88.24% +1.28	93.29% +8.73
Bearish	0%	0% 0	11.76% -1.28	6.71% -8.73

Bullish· Jul 23

The company's GLP-1 preclinical package is expected to be released in the next few months, potentially leading to a huge partnership deal with a big pharma company.
The company's partnership with a dedicated $1.1 billion fund for small company acquisitions and a highly qualified sales force makes it an attractive investment opportunity.
The company's GLP-1 program is expected to be a massive deal, potentially worth over $100 million in upfront payments, and will be followed by label expansion studies that will further increase the program's value.

Bearish· Jun 9

The stock has seen a significant sell-off and shorts are in control, with a notable decline in price after a promising data announcement.
The company is based in Israel, which is perceived by some as a potential red flag for pump and dump schemes.
The stock's price targets are considered meaningless, with one example of a stock having a $20 target that has instead traded under $1.

Generated by AI

Topics

Of the messages about PYPD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	83.33%	89.31%
Technical Analysis	—	0%	16.67%	2.83%
Controversies	—	0%	0%	2.83%
Analysts	—	0%	0%	2.52%
Earnings	—	0%	0%	2.52%
Macro	—	0%	0%	0%

Analysts· Sep 12

Analysts are optimistic about PolyPid Ltd. (PYPD) after the company announced presentation of Phase 2 D-PLEX₁₀₀ clinical data.
The presentation of clinical data has driven up interest in PYPD stock, with some traders considering it a resilient investment opportunity.
The European Society for Coloproctology Scientific Conference is a significant event for PolyPid Ltd., highlighting the company's presence in the medical field.

Announcements· Jun 9

PolyPid's Phase 3 SHIELD II trial of D-PLEX100 for surgical site infection prevention demonstrated a 38% reduction in primary endpoint events and met all key secondary endpoints.
The trial results showed a significant reduction in deep and superficial SSI rates, as well as a 62% reduction in patients with a high ASEPSIS score, with no safety concerns raised by the independent Data Safety Monitoring Board.
PolyPid expects to submit a New Drug Application to the FDA in early 2026 and plans to follow with a Marketing Authorization Application in the EU, with a total addressable market estimated at $6 billion in the US and $10 billion globally.

Technical Analysis· Sep 12

$PYPD is in an overextended position, but the daily chart is signaling a gap fill to $2.55 with potential for significant price movement.
The stock needs to break $1.68 to head into higher prices, with key levels to watch including $1.94 support and $2.20 resistance.
A gap fill is expected, with the next key zone at $2.55 and potential for a breakout above $2.20.

Generated by AI

Community

Of the messages about PYPD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	93.33%	57.89%	60.73%
Newcomers	0%	6.67%	42.11%	39.27%

Regulars· Aug 12

The regulars are focused on the upcoming PDUFA (PDUFA is a FDA approval process) and expect a pre-PDUFA run-up in October-November, with a potential major increase in stock price.
The company's cash position is a concern, with some users questioning the $6.6 million cash on hand when the company received $30 million from a partner, and others hoping for more transparency on the company's financials.
The regulars are optimistic about the company's future, with some users sharing inspiring messages and others celebrating the company's progress and milestones, such as the expected submission of a Marketing Authorization Application to the European Medicines Agency in Q3 2026.

Newcomers· Jul 29

The FDA has accepted PolyPid's NDA for D-PLEX₁₀₀ with Priority Review, with a target action date of November 28, 2026, and a $15 million milestone payment.
This acceptance validates the critical medical need for PolyPid's surgical infection solution and unlocks a $15 million milestone payment, with a total of $30 million in recent upfront capital.
PolyPid's cash runway has been boosted to a robust ~$41 million, eliminating near-term financing risks and funding operations comfortably into 2027.

Generated by AI

PolyPid

Social

Sep 1

Bullish· Jul 23

Bearish· Jun 9

Analysts· Sep 12

Announcements· Jun 9

Technical Analysis· Sep 12

Regulars· Aug 12

Newcomers· Jul 29

PolyPid Announces Participation in Upcoming Fall Investor Conferences

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline

Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA) and PolyPid (PYPD)

PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...

PolyPid Ltd. Q2 2026 Earnings Call Summary

Also Discussed

PolyPid Ltd.

Company Information

Location

PolyPid Announces Participation in Upcoming Fall Investor Conferences

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline

Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA) and PolyPid (PYPD)

PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...

PolyPid Ltd. Q2 2026 Earnings Call Summary

Also Discussed

Social

Sep 1

Bullish· Jul 23

Bearish· Jun 9

Analysts· Sep 12

Announcements· Jun 9

Technical Analysis· Sep 12

Regulars· Aug 12

Newcomers· Jul 29